The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Serum hepcidin concentration is potentially affected by inflammation and iron stores in chronic liver disease (CLD), but little is known about the relationship between hepcidin and the degree of hepatic fibrosis. We investigated the potential role of serum hepcidin as a biomarker of advanced liver disease. Methods: Serum hepcidin was measured in 332 adults with CLD of varying aetiologies, 45 healthy and 50 non‐liver disease patient controls. Liver biopsy data were available for 228 CLD subjects. Results: Hepcidin was decreased in CLD patients compared with non‐liver disease patient controls (P < 0.0001) but not healthy controls, and was lowest in those with cirrhosis (P < 0.0001). Serum hepcidin correlated with hepatic hepcidin mRNA expression in 91 biopsy samples available for genetic analysis (r = 0.68, P < 0.0001). Hepcidin also correlated positively with serum ferritin concentration, transferrin saturation, ALT, serum albumin and haemoglobin, but negatively with serum bilirubin. The hepcidin:ferritin ratio was significantly lower in CLD subjects compared with healthy and disease controls, and decreased with each increase in the stage of fibrosis and siderosis. The hepcidin:ferritin ratio was associated with progressive fibrosis on linear regression, and a value of less than 0.1 was independently associated with cirrhosis on logistic regression analyses (OR 5.54, P < 0.001). Receiver operating characteristic analysis showed the hepcidin:ferritin ratio was able to distinguish between F 0 and F 4 stages of fibrosis (area under receiver operating characteristic curve = 0.86). Conclusions: The hepcidin:ferritin ratio is reduced in relation to increasing fibrosis in CLD and the use of this ratio may have potential future diagnostic implications as a marker of cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Hepcidin and iron regulation, 10 years later
Ganz, T. (2011) · Blood · doi:10.1182/blood-2011-01-258467 · Cited by 962 · cited 1×
“Hepatic expression of hepcidin is decreased in iron deficiency to facilitate iron absorption, and increased in iron repletion to prevent pathological iron overload (3).”
BackgroundFerritins: A family of molecules for iron storage, antioxidation and more
Arosio, P., Ingrassia, R., & Cavadini, P. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.004 · Cited by 886 · cited 2×
“Ferritin is also increased in response to iron overload and systemic inflammation (10, 11).”
BackgroundSerum hepcidin: reference ranges and biochemical correlates in the general population
Galesloot, T. E., Vermeulen, S. H., Geurts-Moespot, A. J., Klaver, S. M., Kroot, J. J., van Tienoven, D., Wetzels, J. F. M., Kiemeney, L. A. L. M., Sweep, F. C., den Heijer, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337907 · Cited by 303 · cited 1×
“Studies to date have reported a significant correlation between hepcidin and ferritin in the serum (15).”
BackgroundHepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C
Fujita, N., Sugimoto, R., Takeo, M., Urawa, N., Mifuji, R., Tanaka, H., Kobayashi, Y., Iwasa, M., Watanabe, S., Adachi, Y., et al. (2007) · Molecular Medicine · doi:10.2119/2006-00057.fujita · Cited by 211
Iron in Nonhemochromatotic Liver Disorders
Alla, V., & Bonkovsky, H. L. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-923317 · Cited by 124
Reduction of serum hepcidin by hemodialysis in pediatric and adult patients
Zaritsky, J., Young, B., Gales, B., Wang, H.-J., Rastogi, A., Westerman, M., Nemeth, E., Ganz, T., & Salusky, I. B. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08161109 · Cited by 107
Cited by
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Hepcidin in the diagnosis of iron disorders
Girelli, D., Nemeth, E., & Swinkels, D. W. (2016) · Blood · doi:10.1182/blood-2015-12-639112 · Cited by 417
Iron and liver fibrosis: Mechanistic and clinical aspects
Mehta, K. J., Farnaud, S. J., & Sharp, P. A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i5.521 · Cited by 269
Low Serum Hepcidin Is Associated With Reduced Short‐Term Survival in Adults With Acute Liver Failure
Spivak, I., Arora, J., Meinzer, C., Durkalski‐Mauldin, V., Lee, W. M., Trautwein, C., Fontana, R. J., & Strnad, P. (2019) · Hepatology · doi:10.1002/hep.30486 · Cited by 32
Metadata
- Authors
- Tan, T. C. H., Crawford, D. H. G., Franklin, M. E., Jaskowski, L. A., Macdonald, G. A., Jonsson, J. R., Watson, M. J., Taylor, P. J., & Fletcher, L. M.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2012-06-07
- Volume
- 32
- Issue
- 9
- Pages
- 1391-1399
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2108481106
- Cited by
- 72
- References
- 7
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. https://app.cochat.ai/papers/10.1111/j.1478-3231.2012.02828.x
- The paper
- Tan, T. C. H., Crawford, D. H. G., Franklin, M. E., Jaskowski, L. A., Macdonald, G. A., Jonsson, J. R., Watson, M. J., Taylor, P. J., & Fletcher, L. M. (2012). The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver International. https://doi.org/10.1111/j.1478-3231.2012.02828.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.